Rialto Wealth Management’s Spero Therapeutics SPRO Stock Holding History

Rialto Wealth Management’s Portfolio SPRO Stock Details SPRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$381	Buy	+172	New	+$450	﹤0.01%	1784

Other funds holding SPRO

GSK plc London $602M AUM

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Rialto Wealth Management's SPRO Position: Q2 2026 in Review

Rialto Wealth Management opened a new position in Spero Therapeutics (SPRO) in Q2 2026: 172 shares worth $381. The stake represents ﹤0.01% of the portfolio and ranks #1784 among its holdings.

60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

Rialto Wealth Management held 172 shares of Spero Therapeutics worth $381 as of Q2 2026.
Spero Therapeutics was a new Rialto Wealth Management position in Q2 2026.
Spero Therapeutics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #1784 holding.
60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.